Biotech | August 10, 2021
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
The goal for the project is the identification and optimization of anti-viral compounds.
Ibuprofen and Famotidine tablets approved by FDA
Drug formulations and biologics make impressive gains
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
The company posted net profit f Rs.85.45 crores for the period ended June 30, 2020.
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The company has reported total income of Rs.355.43 crores during FY 2020-21
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
Subscribe To Our Newsletter & Stay Updated
